2017
DOI: 10.1097/sla.0000000000001920
|View full text |Cite
|
Sign up to set email alerts
|

Substantial Decrease in Comorbidity 5 Years After Gastric Bypass

Abstract: Objective: To evaluate effect on comorbid disease and weight loss five years after Roux-en-Y gastric bypass (RYGB) surgery for morbid obesity in a large nationwide cohort. Summary Background Data:The number patients having surgical procedures to treat obesity and obesity-related disease are increasing. Yet, population-based, long-term outcome studies are few. Results: BMI decreased from 42.8 ±5.5 to 31.2 ±5.5 kg/m 2 at five years, corresponding to 27.7%-reduction in total body weight. Prevalence of T2DM was re… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

3
28
0

Year Published

2017
2017
2023
2023

Publication Types

Select...
9

Relationship

4
5

Authors

Journals

citations
Cited by 84 publications
(31 citation statements)
references
References 19 publications
3
28
0
Order By: Relevance
“…Gastric bypass surgery is a safe and effective treatment for morbid obesity [ 1 , 2 ]. Mean weight loss remains high even after long-term follow-up [ 3 ].…”
Section: Introductionmentioning
confidence: 99%
“…Gastric bypass surgery is a safe and effective treatment for morbid obesity [ 1 , 2 ]. Mean weight loss remains high even after long-term follow-up [ 3 ].…”
Section: Introductionmentioning
confidence: 99%
“…1,23 In the present cohort, BMI and HbA 1c concentration were reduced in the GBP group 1 year postoperatively compared with the controls, in accordance with published 5-year results on approximately 25 000 patients from the SOReg who underwent GBP. 8 The rapid improvement in metabolic control after bariatric surgery may entail a risk for paradoxical deterioration in preexisting DR. 24,25 In the Diabetes Control and Complications Trial, 13.1% of 711 patients with type 1 diabetes in the intensive treatment group had early worsening of DR compared with 7.6% of 728 patients in the conventional treatment group. 26 More re-cently, in the clinical trial evaluating semaglutide (SUSTAIN [Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes]), a glucagon-like peptide-1 receptor agonist for the treatment of diabetes, a significant increase in the risk for DR complications was observed compared with placebo.…”
Section: Discussionmentioning
confidence: 99%
“…If symptoms remain -or new ones emerge -several years postoperatively, this may lead to disappointment and a feeling of hopelessness. Rumination, a type of emotion-focused coping with a repetitive focus on possible causes and consequences of ambiguous symptoms, has been found to predict the severity of depressive symptoms (28) .…”
Section: Discussionmentioning
confidence: 99%